These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38761408)

  • 21. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
    Askanase AD; D'Cruz D; Kalunian K; Merrill JT; Navarra SV; Cahuzac C; Cornelisse P; Murphy MJ; Strasser DS; Trokan L; Berkani O
    Lancet Rheumatol; 2024 Nov; ():. PubMed ID: 39586304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
    Borchmann P; Ferdinandus J; Schneider G; Moccia A; Greil R; Hertzberg M; Schaub V; Hüttmann A; Keil F; Dierlamm J; Hänel M; Novak U; Meissner J; Zimmermann A; Mathas S; Zijlstra JM; Fosså A; Viardot A; Hertenstein B; Martin S; Giri P; Scholl S; Topp MS; Jung W; Vucinic V; Beck HJ; Kerkhoff A; Unger B; Rank A; Schroers R; Zum Büschenfelde CM; de Wit M; Trautmann-Grill K; Kamper P; Molin D; Kreissl S; Kaul H; von Tresckow B; Borchmann S; Behringer K; Fuchs M; Rosenwald A; Klapper W; Eich HT; Baues C; Zomas A; Hallek M; Dietlein M; Kobe C; Diehl V; ; ; ; ;
    Lancet; 2024 Jul; 404(10450):341-352. PubMed ID: 38971175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.
    Tseng KY; Yang MY; Chen WS; Jiang JK; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang YW; Lin YZ; Chang CY; Teng HW
    Int J Colorectal Dis; 2024 Dec; 39(1):195. PubMed ID: 39630293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are we making progress in curing advanced cervical cancer-again?
    Lindegaard JC; Petric P; Tan LT; Hoskin P; Schmid MP; Jürgenliemk-Schulz I; Mahantshetty U; Kirisits C; Pötter R
    Int J Gynecol Cancer; 2024 Dec; 34(12):1940-1945. PubMed ID: 38986568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.
    Masana L; Zambon A; Schmitt CP; Taylan C; Driemeyer J; Cohen H; Buonuomo PS; Alashwal A; Al-Dubayee M; Kholaif N; Diaz-Diaz JL; Maatouk F; Martinez-Hervas S; Mangal B; Löwe S; Cunningham T
    Lancet Diabetes Endocrinol; 2024 Dec; 12(12):880-889. PubMed ID: 39426393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE;
    Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT.
    Crawley E; Anderson E; Cochrane M; Shirkey BA; Parslow R; Hollingworth W; Mills N; Gaunt D; Treneman-Evans G; Rai M; Macleod J; Kessler D; Pitts K; Cooper S; Loades M; Annaw A; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Metcalfe C
    Health Technol Assess; 2024 Oct; 28(70):1-134. PubMed ID: 39485730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Risk Factors, and Development and Validation of Prognostic Prediction Models for Distant Metastasis in Patients With Rectal Cancer: A Study Based on the SEER Database and a Chinese Population.
    Zhang H; Wang H; Yao Y; Liu L; Feng F; Li H; Sun C
    Cancer Control; 2024; 31():10732748241303650. PubMed ID: 39579008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
    Dawson R; Diacon AH; De Jager V; Narunsky K; Moodley VM; Stinson KW; Liu Y; Zheng B; Hafkin J
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39612928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.
    Yu N; Chen X; Li J; Kang X; Wang Z; Zhang R; Qin J; Li Y; Zheng Q; Feng G; Deng L; Zhang T; Wang W; Liu W; Wang J; Feng Q; Lv J; Zhou Z; Xiao Z; Bi N; Li Y; Wang X
    Strahlenther Onkol; 2024 Dec; 200(12):1038-1046. PubMed ID: 39134689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
    Yao L; Zhang C; Li D; Xu L; Yang X
    Medicine (Baltimore); 2024 Nov; 103(45):e40320. PubMed ID: 39533634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How Does Shame Relate to Clinical and Psychosocial Outcomes in Knee Osteoarthritis?
    Yeo JY; Lim CJ; Yang SY; Tan BY
    Clin Orthop Relat Res; 2024 Dec; ():. PubMed ID: 39625176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
    Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy.
    Wang X; He Y; Li J; Wang T; Fan Z; Ouyang T
    BMC Womens Health; 2024 Nov; 24(1):629. PubMed ID: 39604957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
    Zhang H; Li Q; Li C; Wu M; Chen H; Li Y; You F; Zhao Y; Jin J; Chen X; Ding Y
    Lancet Rheumatol; 2024 Dec; 6(12):e837-e847. PubMed ID: 39454617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.